CDEK
← All drugs Report issue

vorapaxar

Trade name: zontivity

Small moleculeapprovedFast Track FDA

Approved

May 8, 2014

Vorapaxar is a tricyclic himbacine-derived oral thrombin receptor antagonist that acts by reversible inhibition of the protease-activated receptor-1 (PAR-1). PAR-1 is expressed on platelets and its inhibition prevents platelets from aggregation. Vorapaxar is approved by FDA and is indicated for the reduction of recurring thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease. Vorapaxar at the same time may cause bleeding complications including intracranial haemorrhage (ICH), when compared to standard therapy alone. That is why Vorapaxar is contraindicated in patients with prior stroke, transient ischemic attack and ICH. — NCATS

Clinical trial activity

16 trials · 13 clinical orgs · 5 marketing orgs

Phase 1
2
Phase 2
8
Phase 3
3
Phase 4
7

Earliest trial started Aug 30, 2005 (NCT00132912)

Timeline

2000s

  1. Jan 1, 2005

    Merck — Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2007

    Merck — Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Merck — Earliest Phase 1 Sponsor(trial)

  2. May 8, 2014

    Merck — Earliest FDA Approval

  3. May 8, 2014

    Xspire Pharma — Marketing Organization

  4. May 8, 2014

    Merck — NDA Organization

  5. May 8, 2014

    Aralez Pharmaceuticals — NDA Secondary Org

  6. May 8, 2014

    AstraZeneca — Marketing Organization

  7. May 8, 2014

    Xspire Pharma — NDA Secondary Org

  8. May 8, 2014

    KEY THERAP — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedFast trackMay 8, 2014

Chemistry & pharmacology

Loading structure…

SMILES

CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@H]1C(=O)O[C@H](C)[C@H]1[C@H]2/C=C/c1ccc(-c2cccc(F)c2)cn1
Mol. weight
492.59 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Discontinued

Oral

Yes

Parenteral

No

Topical

No

Black box warningFirst in class

Sources

Also known as

  • [(1r,3ar,4ar,6r,8ar,9s,9as)-9-{(e)-2-[5-(3-fluorophényl)-2-pyridinyl]vinyl}-1-méthyl-3-oxododécahydronaphto[2,3-c]furan-6-yl]carbamate d'éthyle
  • [(1r,3ar,4ar,6r,8ar,9s,9as)-9-{(e)-2-[5-(3-fluorophényl)-2-pyridinyl]vinyl}-1-méthyl-3-oxododécahydronaphto[2,3-c]furan-6-yl]carbamate d'éthyle
  • carbamic acid, [(1r,3ar,4ar,6r,8ar,9s,9as)-9-[(1e)-2-[5-(3-fluorophenyl)-2- pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester
  • carbamic acid, [(1r,3ar,4ar,6r,8ar,9s,9as)-9-[(1e)-2-[5-(3-fluorophenyl)-2- pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester
  • carbamic acid, n-[(1r,3ar,4ar,6r,8ar,9s,9as)-9-[(e)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester
  • carbamic acid, n-[(1r,3ar,4ar,6r,8ar,9s,9as)-9-[(e)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl ester
  • ethyl n-[(3r,3as,4s,4ar,7r,8ar,9ar)-4-[(e)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3h-benzo[f]isobenzofuran-7-yl]carbamate
  • ethyl n-[(3r,3as,4s,4ar,7r,8ar,9ar)-4-[(e)-2-[5-(3-fluorophenyl)-2-pyridyl]vinyl]-3-methyl-1-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-3h-benzo[f]isobenzofuran-7-yl]carbamate
  • sch530348
  • sch530348
  • sch 530348
  • sch 530348
  • sch 530348
  • sch 530348
  • sch-530348
  • sch-530348
  • sch-530348
  • sch-530348
  • vorapaxar
  • vorapaxar
  • vorapaxar
  • vorapaxar
  • vorapaxar
  • vorapaxar
  • vorapaxar
  • vorapaxar
  • vorapaxar
  • vorapaxar sulfate
  • vorapaxar sulfate
  • vorapaxar sulfate
  • vorapaxar sulfate
  • vorapaxar sulfate
  • zontivity
  • zontivity
  • zontivity
  • zontivity

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02975583Phase 4Dec 1, 2016Merck, Vanderbilt University
NCT02660866Phase 4Jul 1, 2016Department of Veteran Affairs
NCT02875028Phase 4Jun 1, 2016University of Vienna
NCT02548650Phase 4Mar 1, 2016Merck, University of Florida
NCT02545933Phase 4Feb 1, 2016Merck, University of Florida
NCT02629367Phase 4Jan 1, 2016Inova Health System
NCT03207451Phase 4Jan 1, 2016Inova Health System, Merck
NCT02394730Phase 1/Phase 2 (Phase 2)Sep 1, 2015Merck, National Institute of Allergy and Infectious Diseases (NIAID), University of Melbourne, University of Minnesota, University of New South Wales
NCT02475837Phase 2Aug 1, 2015Merck, Stanford University
NCT01358344Phase 1Aug 1, 2010Merck
NCT00617123Phase 3Jul 1, 2008Duke University, Merck, Thrombolysis in Myocardial Infarction Study Group
NCT00527943Phase 3Dec 1, 2007Duke University, Merck
NCT00526474Phase 3Sep 1, 2007Merck, Thrombolysis in Myocardial Infarction Study Group
NCT00684203Phase 2Dec 1, 2006Merck
NCT00684515Phase 2Sep 21, 2006Merck
NCT00132912Phase 2Aug 30, 2005Merck
Showing 16 of 16 trials
Page 1 / 1

Organizations

Research & Development (13)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
MerckFor profit13742005
Duke UniversityAcademic/Hospital2012007
Inova Health SystemAcademic/Hospital2212016
Thrombolysis in Myocardial Infarction Study GroupAcademic/Hospital2012007
University of FloridaAcademic/Hospital2212016
Department of Veteran AffairsGovernment1112016
National Institute of Allergy and Infectious Diseases (NIAID)Government1012015
Stanford UniversityAcademic/Hospital1112015
University of MelbourneAcademic/Hospital1012015
University of MinnesotaAcademic/Hospital1012015
University of New South WalesAcademic/Hospital1112015
University of ViennaAcademic/Hospital1112016
Vanderbilt UniversityAcademic/Hospital1112016
13 organizations
Page 1 / 1

Marketing (6)

OrganizationOrg typeRelationshipDate
Aralez PharmaceuticalsFor profitNDA2May 8, 2014
AstraZenecaFor profitMKTGMay 8, 2014
KEY THERAPFor profitMKTGMay 8, 2014
MerckFor profitNDAMay 8, 2014
Xspire PharmaFor profitMKTGMay 8, 2014
Xspire PharmaFor profitNDA2May 8, 2014